跳至主要内容
临床试验/NL-OMON51424
NL-OMON51424招募中不适用

Clinical validation of transrectal multiparametric ultrasound imaging strategy (PCaVision) for the detection of clinically significant prostate cancer: a head-to-head comparison with the MRI-based strategy - PCaVision

Amsterdam UMC0 个研究点目标入组 438 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
438

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • age of 18 years or older
  • biopsy naïve
  • clinical suspicion of prostate cancer for which prostate MRI is indicated
  • signed informed consent

排除标准

  • a patient history with a cardiac right-to-left shunt.
  • allergic to sulphur hexafluoride or any of the other ingredients of the
  • ultrasound contrast agent SonoVue
  • current treatment with dobutamine
  • known severe pulmonary hypertension (pulmonary artery pressure >90 mmHg),
  • uncontrolled systemic hypertension or respiratory distress syndrome
  • any (further) contraindication to undergo MRI or 3D mpUS imaging
  • PSA level above or equal to 100 ng/ml
  • Medical history of prostate surgery
  • current treatment of 5 alpha-reductase inhibitors for at least 3 months
  • incapable of understanding the language in which the patient information is

研究者

发起方
Amsterdam UMC

相似试验